Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Vucic, Steve
COURAGE-ALS, NCT04944784 / 2020-004040-29: A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)	Terminated	3	486	Europe, Canada, US, RoW	Reldesemtiv, Placebo	Cytokinetics	Amyotrophic Lateral Sclerosis	07/23	07/23
COURAGE OLE, NCT05442775 / 2021-004727-33: A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)	Terminated	3	71	Europe, Canada, US, RoW	Reldesemtiv	Cytokinetics, Cytokinetics Inc	Amyotrophic Lateral Sclerosis	06/23	06/23
AMBALS, NCT05959850: A Double-blind Randomised, Placebo-controlled Clinical Trial to Test Ambroxol Treatment in ALS	Recruiting	2	50	RoW	Ambroxol, Ambroxol Hydrochloride, Placebo	The Florey Institute of Neuroscience and Mental Health, Mobius Medical Pty Ltd., The University of Queensland	Amyotrophic Lateral Sclerosis	06/24	12/24